Clerio Vision Is Launching $25 million Series E2 Round of Financing

Manhattan, New York, March 20th, 2023 - Bridge Point Capital, a leading private equity investment firm, is proud to announce that its portfolio company Clerio Vision is about to launch a $25 million Series E2 funding round. The funding will be led by Safar Partners and include participation from a top Pension Fund in Australia, Bridge Point Capital, and other prestigious investors.

Clerio Vision is a cutting-edge ophthalmic medical device company that develops advanced vision correction solutions using femtosecond laser technology. With this new funding, the company plans to expand its business to other countries, particularly in Asian markets, and to further invest in research and development, including presbyopia, myopia control, and intraocular lenses (IOLs).

Clerio Vision’s LIRIC (Laser Induced Refractive Index Change) technology is a unique, minimally invasive method for correcting a patient’s visual aberrations with a laser. This is a potentially seismic shift in how to correct the eye’s refractive errors in the future.

With all current refractive surgery techniques, a laser is used to cut and ablate eye tissue. But with LIRIC, a femtosecond laser can be used at low energy levels – below the ablation threshold – so no cutting or ablation of tissues occurs. LIRIC works by changing the refractive index across your visual field to provide patients with their best possible vision.

FIGURE 1. Whereas LASIK corrects vision by using a laser to ablate and remove layers of tissue, and thereby change the shape of the cornea, LIRIC changes the focusing capability of the cornea's internal optics noninvasively.

"We are thrilled to launch this funding, which will enable us to bring our innovative technology to even more people around the world," said Mike Totterman, Chairman of Clerio Vision. "We are excited to partner with Bridge Point Capital and our new investors to advance our mission of revolutionizing the field of vision correction."

Mark Young, Managing Partner of Bridge Point Capital, said, "We are proud to support Clerio Vision and their groundbreaking work in the field of vision correction. With this new funding, we believe the company is well-positioned to expand its reach and impact in the market. We look forward to working with Clerio Vision to continue driving innovation in ophthalmic medical devices."

About Clerio Vision:

Clerio Vision is a leading ophthalmic medical device company that develops advanced vision correction solutions using femtosecond laser technology. The company's innovative technology offers a non-invasive and safe alternative to traditional surgical procedures and has the potential to revolutionize the field of vision correction.

About Bridge Point Capital:

Bridge Point Capital is a leading private equity investment firm that invests in high-growth companies in various sectors, including healthcare and technology. The firm provides capital, strategic guidance, and operational expertise to help its portfolio companies achieve their full potential.

For other information regarding Clerio Vision and this fund raise, please reach out to us now:

mark.young@bridgepoint.capital

(914) 826-3190